688278.SH
Xiamen Amoytop Biotech Co. Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 44.43
+5.96%Year over year
Reported trailing growth
- Revenue
- +29.7%
- EBITDA
- —
- EBIT
- +20.5%
- EPS
- +14.7%
- Free cash flow
- +18.3%
- Operating cash flow
- +17.6%
Forward estimates
Based on analyst estimates
- Revenue
- -37.3%
- EBITDA
- -35.8%
- EPS
- -33.6%
Three-year CAGR
- Revenue
- +34.3%
- EBITDA
- +45.3%
- EBIT
- +45.4%
- Net income
- +53.2%
- EPS
- +52.7%
- Free cash flow
- +48.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026